Fusion Antibodies (LSE:FAB) Common Stock : £2.38 Mil (As of Sep. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Fusion Antibodies Common Stock?

Fusion Antibodies's quarterly common stock stayed the same from Sep. 2022 (£1.04 Mil) to Mar. 2023 (£1.04 Mil) but then increased from Mar. 2023 (£1.04 Mil) to Sep. 2023 (£2.38 Mil).

Fusion Antibodies's annual common stock increased from Mar. 2021 (£1.02 Mil) to Mar. 2022 (£1.04 Mil) but then stayed the same from Mar. 2022 (£1.04 Mil) to Mar. 2023 (£1.04 Mil).

Fusion Antibodies Common Stock Historical Data

The historical data trend for Fusion Antibodies's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fusion Antibodies Common Stock Chart

Fusion Antibodies Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Common Stock

Get a 7-Day Free Trial

0.88

1.02

1.04

Fusion Antibodies Semi-Annual Data
	Mar15	Mar16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Common Stock	Get a 7-Day Free Trial											1.04	1.04	1.04	1.04	2.38

Fusion Antibodies Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Fusion Antibodies (LSE:FAB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fusion Antibodies PLC (LSE:FAB) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

1 Springbank Road, Springbank Industrial Estate, Dunmurry, Belfast, GBR, BT17 0QL

Website

https://www.fusionantibodies.com

Fusion Antibodies PLC offers a range of antibody engineering services for all stages of therapeutic and diagnostic antibody development. It is engaged in the research, development, and manufacturing of recombinant proteins, particularly in the areas of cancer and infectious diseases. Its services include antibody sequencing, antibody humanization, stable cell line development, monoclonal antibody production, and transient protein expression. Geographically company generates the majority of its revenue from North America.

Fusion Antibodies (LSE:FAB) Headlines

From GuruFocus

626 Financial, LLC Buys 3, Sells 2 in 3rd Quarter

By GuruFocus Research GuruFocus Editor • 10-21-2022